Ipsen nominates Peter Guenter to its Board of Directors

Core Viewpoint - Ipsen has appointed Peter Guenter as a new Director on its Board, effective January 28, 2026, filling the vacancy left by Henri Beaufour [1][9]. Group 1: Appointment Details - Peter Guenter brings nearly 40 years of experience in the global pharmaceutical industry, having most recently served as CEO of Merck Healthcare from 2021 to 2025 [2]. - His previous roles include CEO at Almirall, where he focused on medical dermatology, and over 20 years at Sanofi, where he joined the Executive Committee in 2013 [2][3]. - Following this appointment, Ipsen's Board will consist of 14 directors, equally divided between men and women, including five independent directors and two employee representatives [3]. Group 2: Shareholder Meeting - A request for ratification of Peter Guenter's appointment will be presented at the next Shareholders' meeting, which will remain effective until the 2027 Shareholders' meeting [4]. Group 3: Company Overview - Ipsen is a global biopharmaceutical company focused on transformative medicines in oncology, rare diseases, and neuroscience, with nearly 100 years of development experience [5]. - The company operates in over 40 countries and partners globally to deliver medicines to more than 100 countries [5].